Marc Tessier-Lavigne

Insider Reports History

Location
1 Dna Way, South San Francisco, CA
Signature
/s/ Tyler Nielsen, by power of attorney
All insider transactions
Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by Marc Tessier-Lavigne:

Stock Role Class Num Shares Value Price $ Report Date Ownership
Denali Therapeutics Inc. Director Common Stock 1.89M $31M $16.44 Jun 3, 2025 Direct
REGENERON PHARMACEUTICALS, INC. Director Common Stock 2.43K $2.32M $951.26 Jan 3, 2023 Direct
Denali Therapeutics Inc. Director Common Stock 79.2K $1.3M $16.44 Jun 3, 2025 The Tessier-Lavigne/Hynes Irrevocable Trust 2
Denali Therapeutics Inc. Director Common Stock 78.8K $1.3M $16.44 Jun 3, 2025 The Tessier-Lavigne/Hynes Irrevocable Trust 1
Denali Therapeutics Inc. Director Common Stock 78.8K $1.3M $16.44 Jun 3, 2025 The Tessier-Lavigne/Hynes Irrevocable Trust 3
Denali Therapeutics Inc. Director Stock Option (right to buy) 18.1K Jun 3, 2025 Direct
REGENERON PHARMACEUTICALS, INC. Director Non-Qualified Stock Option (right to buy) 1.93K Jan 3, 2023 Direct

Insider Reports Filed by Marc Tessier-Lavigne

Symbol Company Period Transactions Value $ Form Type Date Filed Role
DNLI Denali Therapeutics Inc. Jun 3, 2025 2 $0 4 Jun 5, 2025 Director
DNLI Denali Therapeutics Inc. May 31, 2024 2 $0 4 Jun 4, 2024 Director
DNLI Denali Therapeutics Inc. Jun 1, 2023 2 $0 4 Jun 5, 2023 Director
REGN REGENERON PHARMACEUTICALS, INC. Jan 3, 2023 2 $0 4 Jan 5, 2023 Director
REGN REGENERON PHARMACEUTICALS, INC. Jan 3, 2023 2 $0 4 Jan 5, 2023 Director
DNLI Denali Therapeutics Inc. Nov 23, 2022 1 -$610K 4 Nov 28, 2022 Director
DNLI Denali Therapeutics Inc. Nov 1, 2022 2 -$605K 4 Nov 3, 2022 Director
REGN REGENERON PHARMACEUTICALS, INC. Sep 29, 2022 20 -$3.13M 4 Oct 3, 2022 Director
DNLI Denali Therapeutics Inc. Sep 28, 2022 2 -$616K 4 Sep 30, 2022 Director
DNLI Denali Therapeutics Inc. Aug 23, 2022 2 -$632K 4 Aug 25, 2022 Director
DNLI Denali Therapeutics Inc. Jul 25, 2022 2 -$712K 4 Jul 27, 2022 Director
DNLI Denali Therapeutics Inc. Jun 23, 2022 3 -$1.84M 4 Jun 27, 2022 Director
DNLI Denali Therapeutics Inc. Jun 2, 2022 2 $0 4 Jun 6, 2022 Director
DNLI Denali Therapeutics Inc. Mar 23, 2022 2 -$677K 4/A Jun 28, 2022 Director
REGN REGENERON PHARMACEUTICALS, INC. Mar 21, 2022 3 -$2.3M 4 Mar 23, 2022 Director
REGN REGENERON PHARMACEUTICALS, INC. Mar 16, 2022 6 -$3.69M 4 Mar 18, 2022 Director
REGN REGENERON PHARMACEUTICALS, INC. Jan 3, 2022 2 $0 4 Jan 5, 2022 Director
DNLI Denali Therapeutics Inc. Dec 31, 2021 1 $0 5 Feb 17, 2022 Director
DNLI Denali Therapeutics Inc. Dec 28, 2021 16 -$2.81M 4 Dec 30, 2021 Director
REGN REGENERON PHARMACEUTICALS, INC. Dec 9, 2021 3 -$1.11M 4 Dec 10, 2021 Director
REGN REGENERON PHARMACEUTICALS, INC. Sep 13, 2021 23 -$4.69M 4 Sep 15, 2021 Director
DNLI Denali Therapeutics Inc. Jun 7, 2021 8 -$4.87M 4 Jun 8, 2021 Director
DNLI Denali Therapeutics Inc. Jun 2, 2021 2 $0 4 Jun 4, 2021 Director
DNLI Denali Therapeutics Inc. May 21, 2021 2 -$2.81M 4 May 24, 2021 Director